Keros Therapeutics (KROS) Assets Average (2020 - 2025)

Keros Therapeutics has reported Assets Average for 6 years, with the latest figure at $540.4 million in Q4 2025.

• For the quarter ending Q4 2025, Assets Average fell 9.57% year-over-year to $540.4 million; the trailing twelve-month figure through Dec 2025 stood at $540.4 million (down 9.57% YoY), and the FY2025 full-year result was $477.0 million, down 3.25% from the prior year.
• Assets Average for Q4 2025 stood at $540.4 million, down from $750.0 million in the prior quarter.
• The five-year high for Assets Average was $770.9 million in Q2 2025, with the low at $230.9 million in Q2 2022.
• Historically, Assets Average has averaged $408.4 million across 5 years, with a median of $346.9 million in 2023.
• Annual changes were most pronounced in 2021 — Assets Average soared 636.82% — and 2025, when it slipped 9.57%.
• Keros Therapeutics' Assets Average stood at $242.6 million in 2021, then rose by 15.28% to $279.7 million in 2022, then rose by 24.48% to $348.1 million in 2023, then jumped by 71.65% to $597.6 million in 2024, then retreated by 9.57% to $540.4 million in 2025.
• The last three Assets Average figures came in at $540.4 million (Q4 2025), $750.0 million (Q3 2025), and $770.9 million (Q2 2025), per Business Quant data.